NOW AVAILABLE IN CANADA
INTRODUCING RYBELSUS®,
THE FIRST AND ONLY
ORAL GLP-1 RA*
RYBELSUS® (semaglutide tablets) is indicated as an adjunct to diet and exercise to impr 1
ed inappropriate due to intolerance or contraindications • in combination with other medicinal products for the treatment of diabetes (see clinical trials in the Product Monograph for patient populations and drug combinations tested) Consult the RYBELSUS® Product Monograph at RYBELSUSPM-E.ca for more information relating to contraindications, warnings and precautions, conditions of clinical use, adverse reactions, drug interactions, and dosing information, which have not been discussed win this advertisement. The Pr * Comparative clinical significance has not been established. GLP-1 RA, glucagon-like peptide-1 receptor agonist. Reference: 1. RYBELSUS® (semaglutide tablets) Product Monograph. Novo Nordisk Canada Inc., 2020.
RYBELSUS® is a registered trademark of Novo Nordisk A/S and used under license by Novo Nordisk Canada Inc. Novo Nordisk Canada Inc., Tel: (905) 629-4222 or 1-800-465-4334. www.novonordisk.ca CA20RYB00009E © Novo Nordisk Canada Inc.
ol